While there seem to be no differences in stemness capacity and long-term engraftment efficiency between the Plerixafor Group and the G-CSF Group in lymphoma as well as myeloma patients, poor mobilizing lymphoma patients per se constitute a high-risk population with a poorer outcome after ASCT. This evidence concerns the gene CSF3 and plasma cell myeloma.